NCT03703778 2025-05-06
READT
Chinese University of Hong Kong
Active not recruiting
Clinical Trials
3 trialsNCT02588404 2024-12-10
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT02128334 2016-08-16
An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation
Astellas Pharma Inc
Completed